Xilio Therapeutics, Inc.
XLO
$0.6844
-$0.0154-2.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.78% | 22.89% | 25.84% | 16.29% | 28.05% |
| Total Depreciation and Amortization | -14.38% | 12.19% | -16.48% | -17.17% | -9.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.88% | -16.26% | -21.99% | -16.39% | -20.01% |
| Change in Net Operating Assets | -108.45% | 808.72% | -261.32% | -255.61% | 7,880.50% |
| Cash from Operations | -172.56% | 375.93% | -5.44% | -2.27% | 220.39% |
| Capital Expenditure | -1,809.52% | -- | -- | -- | 93.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,809.52% | -- | -- | -- | 93.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 99.69% | 98.14% |
| Issuance of Common Stock | -99.78% | 12.16% | 15,088.89% | -50.00% | 14,231.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 136.30% | 406.50% | 601.96% | 99.87% | 2,120.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.74% | 453.88% | 60.42% | 12.31% | 323.55% |